Cargando…
Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
Forty-six previously untreated patients with advanced ovarian cancer were treated with combination chemotherapy comprising cisplatin 80 mg m-2 i.v. and cyclophosphamide 1 gm-2 i.v. every 28 days for 5 cycles. Eighty-five percent of patients received more than 75% of the calculated doses, and of 43 e...
Autores principales: | Green, J. A., Warenius, H. M., Errington, R. D., Myint, S., Spearing, G., Slater, A. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246807/ https://www.ncbi.nlm.nih.gov/pubmed/3219276 |
Ejemplares similares
-
Intensity-modulated radiotherapy combined with sequential cisplatin and fluorouracil chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wu, Mingyao, et al.
Publicado: (2018) -
Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
por: Shen, Jing, et al.
Publicado: (2022) -
Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995) -
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
por: Pronzato, P., et al.
Publicado: (1996) -
A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer.
por: Kehoe, S., et al.
Publicado: (1994)